Contract analysis

I. Purpose and Executive Summary This memorandum provides advisory recommendations to Penterra Pharmaceuticals Corp. ("PPC" or the "Company") for strengthening its transfer pricing positions, contemporaneous documentation, and intercompany arrangements for Tax Year ("TY") 2021 and all subsequent tax years. These recommendations are informed by, and draw directly upon, the lessons learned during the Internal Revenue S

II. Background and Context A. The PPC IP Structure To situate the recommendations that follow, we briefly describe the relevant entities and intercompany arrangements that constitute PPC's international IP structure. Penterra Pharmaceuticals Corp. PPC is a publicly traded specialty pharmaceutical and biotechnology company, listed on the Nasdaq Stock Market under the ticker symbol PPCA and identified by Employer Ident

1. Cost-Sharing Ratios. The IRS asserted that PBI's cost-sharing percentages under the CSA were understated. The IRS's economist, Dr. Alan Washburne, proposed increasing PBI's cost-sharing percentages by 8 to 12 percentage points across the examination years, based on alternative reasonably anticipated benefits projections and a lower discount rate (7.2% weighted average cost of capital vs. PPC's 9.8%). This challeng

2. Legacy IP Royalty Rate. The IRS asserted that the 4.5% royalty rate under the Legacy IP License was below the arm's-length range and proposed increasing the rate to 11.0%. The IRS's position was based on an alternative comparable uncontrolled transaction ("CUT") analysis that identified license agreements purportedly more comparable to PPC's legacy IP than those identified in PPC's documentation. This challenge re

3. PBI Economic Substance / DEMPE Functions. The IRS asserted that PBI lacked sufficient economic substance and that the key Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions associated with PPC's pharmaceutical IP remained in the United States. Under this theory, the IRS argued that PBI was not entitled to the residual profits attributable to the non-Americas IP rights because P

4. PCT Undervaluation. Although TY 2012 (the year of the PCT payment) was outside the Examination years, the IRS used its assertion that the $312 million PCT payment was substantially below arm's length (the IRS asserted the payment should have been $852 million) to support a recharacterization of the ongoing CSA and related arrangements during TY 2017–2020. Total Proposed Adjustments. The IRS's total proposed adjust

III. Recommendations — Transfer Pricing Documentation Enhancements A. Contemporaneous Documentation Under IRC § 6662(e)(3)(B) PPC's existing transfer pricing documentation was prepared by Crestfield & Associates LLP ("Crestfield"), with Transfer Pricing Partner Susan Lam, CPA, and Engagement Partner Martin Ogilvy, CPA, serving as the principal contacts (Crestfield's offices are located at 1200 Avenue of the Americas,

IV. Recommendations — CSA Methodology and Cost-Sharing Calibration A. Reasonably Anticipated Benefits and Cost-Sharing Ratios Under the CSA, PBI's share of the qualified R&D cost pool is determined by reference to PBI's share of the reasonably anticipated benefits ("RABs") from the intangible development activities, consistent with Treasury Regulation § 1.482-7(e). For TY 2017 through TY 2020, PBI's cost-sharing perc

V. Recommendations — PBI Operational Substance and DEMPE Functions A. Overview of the IRS's Economic Substance / DEMPE Challenge During the Examination, the IRS asserted that PBI lacked sufficient economic substance and that the key DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation — associated with PPC's pharmaceutical IP remained concentrated in the United States, specifically at

VI. Recommendations — Intercompany Agreement Maintenance A. CSA Agreement The CSA, originally executed effective July 1, 2012, should be reviewed and, if appropriate, amended to ensure that it reflects current regulatory standards u